We can’t show the full text here under this license.
Abstract
Dulaglutide use at a higher dose may lead to euglycemic diabetic ketoacidosis in patients with type 2 diabetes.
- Dulaglutide is associated with common adverse effects such as fatigue, nausea, and abdominal pain.
- Case reports suggest that GLP-1 receptor agonists can lead to euglycemic diabetic ketoacidosis, despite its typical association with SGLT2 inhibitors.
- A patient experienced gastrointestinal symptoms and weakness after re-initiating dulaglutide at a higher dose.
- Symptoms resolved following treatment with insulin and intravenous fluids.
Simplified